Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04380337 · ClinicalTrials.gov registry record · Phase 2
Organ Preservation Program Using Short-Course Radiation & FOLFOXIRI in Rectal Cancer
A Phase 2 study, sponsored by Stanford University.
- Completed
- Registry status
- Phase 2
- Development phase
- 38
- Enrollment target
NCT04380337: Completed Phase 2 study, sponsored by Stanford University.
NCT04380337 is a Phase 2 study that has completed, run by Stanford University. The registered enrollment target is 38 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (71% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04380337, a Phase 2 study, has completed, sponsored by Stanford University.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 38 participants
- Enrollment target
Study Summary
The purpose of the research is to evaluate whether both chemotherapy and radiotherapy can lead to higher rates of clinical complete response leading to organ preservation in human subjects with cancer. The objective is to learn if this treatment approach may safely be used as an alternative to the standard treatment for rectal cancer and to know the quality-of-life in these patients.
Primary Outcome
Proportion of patients who achieve a clinical complete response following therapy, expressed as a number and proportion without dispersion.
Interventions
- DRUG FOLFOX regimen
- RADIATION IMRT
- DRUG XELOX
- DRUG FOLFOXIRI
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 38 participants |
| Start Date | 2020-05-21 |
| Est. Completion | 2024-01-17 |
| Phase | Phase 2 |
What the finished NCT04380337 record still lists
NCT04380337 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 38 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (71% lower).
The record links to 0 conditions, and to 4 interventions - of which FOLFOX regimen is the first listed.
NCT04380337 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT04380337 about?
NCT04380337 is a clinical study titled "Organ Preservation Program Using Short-Course Radiation & FOLFOXIRI in Rectal Cancer". The purpose of the research is to evaluate whether both chemotherapy and radiotherapy can lead to higher rates of clinical complete response leading to organ preservation in human subjects with cancer. The objective is to learn if this treatment approach may safely be used as an alternative to the s...
What is the current status of trial NCT04380337?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 38 participants. The study started on 2020-05-21. Estimated completion is 2024-01-17.
What interventions are being tested in trial NCT04380337?
The interventions under investigation include: FOLFOX regimen (DRUG), IMRT (RADIATION), XELOX (DRUG), FOLFOXIRI (DRUG).
Who is sponsoring clinical trial NCT04380337?
This trial is sponsored by Stanford University, which has 1,744 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT04380337's enrollment target sits among peer trials
38 1467th of 2000 higher than 517 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01684904 · 38 participants · NA
Proton Therapy for Esophageal Cancer
- NCT03310879 · 38 participants · Phase 2
Study of the CDK4/6 Inhibitor Abemaciclib in Solid Tumors Harboring Genetic Alterations in Genes Encoding D-Type Cyclins or Amplification of CDK4 or CDK6
- NCT03896269 · 38 participants · Phase 1
CPX-351 in Treating Patients With Relapsed or Refractory High Risk Myelodysplastic Syndrome or Chronic Myelomonocytic Leukemia
- NCT04085315 · 38 participants · Phase 1
Alisertib in Combination With Osimertinib in Metastatic EGFR-mutant Lung Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI